Pharmaceutical News

RSS

Diabetic patients may require higher doses of metformin to achieve same anti-cancer activity

A University of Colorado Cancer Center study published online this month in the journal Cell Cycle shows that breast cancer cell growth, motility and aggression is promoted by excess glucose, as experienced by patients with diabetes and metabolic syndrome.

25 Oct 2013

Whitehead Institute scientists identify novel Parkinson's disease drug target

Using a discovery platform whose components range from yeast cells to human stem cells, Whitehead Institute scientists have identified a novel Parkinson's disease drug target and a compound capable of repairing neurons derived from Parkinson's patients.

25 Oct 2013

Study: Investigational drug shows promise against pancreatic cancer

An investigational drug that disrupts tumor blood vessels shows promise against a rare type of pancreatic cancer, scientists at Albert Einstein College of Medicine of Yeshiva University have found. Their results were presented October 20 during a poster session at an international cancer conference.

25 Oct 2013

Hands-free ultrasound device with clot-busting drug safe for ischemic stroke patients

A study led by researchers at The University of Texas Health Science Center at Houston (UTHealth) showed that a hands-free ultrasound device combined with a clot-busting drug was safe for ischemic stroke patients.

25 Oct 2013

Biolinerx Inks In-License Agreement With Israeli Institutions For Type 1 Diabetes Treatment

...

24 Oct 2013

Nelsons introduces new hemorrhoid cream

Nelsons, a 150 year old privately owned company and the UK's largest manufacturer of natural healthcare products, introduces Homeopathic H+Care™ Hemorrhoid Cream.

24 Oct 2013

Alexion Pharma's replacement therapy gets FDA Breakthrough Therapy designation for MoCD Type A

Alexion Pharma International Sàrl, a subsidiary of Alexion Pharmaceuticals, Inc., today announced that the U.S. Food and Drug Administration has granted a Breakthrough Therapy designation to cyclic pyranopterin monophosphate (cPMP, or ALXN1101), an enzyme co-factor replacement therapy for the treatment of patients with molybdenum cofactor deficiency type A, a severe and life-threatening, ultra-rare, genetic metabolic disorder that causes catastrophic and irreversible neurologic damage within the first weeks of life.

24 Oct 2013

Leukemia drug reverses symptoms of colitis in lab tests

A drug currently on the market to treat leukemia reversed symptoms of colitis in lab tests, according to recently published findings by medical researchers with the University of Alberta.

24 Oct 2013

FDA to phase out all inhaler medical products containing CFCs by Dec. 31

The U.S. Food and Drug Administration will complete its phase-out of all inhaler medical products containing chlorofluorocarbons by Dec. 31, 2013. This effort is to comply with an international treaty to protect the ozone layer by phasing out the worldwide production of numerous substances, including CFCs, which contribute to ozone depletion.

24 Oct 2013

Kaiser Permanente researchers named co-recipients of Drug Therapy Research Literature Award

Three Kaiser Permanente Colorado researchers have been named co-recipients of the prestigious Drug Therapy Research Literature Award, an award presented annually by the American Society of Health-System Pharmacists Foundation.

24 Oct 2013

Metformin could serve as radiosensitizer to treat patients with stage III non-small cell lung cancer

Treating aggressive lung cancer with the diabetes drug metformin along with radiation and chemotherapy may slow tumor growth and recurrence, suggests new preliminary findings from researchers at the Perelman School of Medicine at the University of Pennsylvania being presented during an oral abstract session October 28 at the 15th World Conference on Lung Cancer.

24 Oct 2013

State-of-the-art HIV vaccine laboratory opens in Cape Town, South Africa

Fred Hutchinson Cancer Research Center tomorrow will celebrate the grand opening of a state-of-the-art HIV vaccine laboratory in Cape Town, South Africa.

24 Oct 2013

Testosterone treatment in hypogonadal men may reduce cardiovascular disease risk

Research from Boston University School of Medicine suggests that testosterone treatment in hypogonadal (testosterone deficient) men restores normal lipid profiles and may reduce the risk of cardiovascular disease. These finding currently appear online in the International Journal of Clinical Practice.

24 Oct 2013

New flu vaccine offers better protection against circulating flu viruses

Last year's flu season was considered one of the strongest and deadliest in recent decades, according to the CDC. In preparation for this year's flu season, Concentra, a subsidiary of Humana Inc., offers a flu vaccine to provide greater protection against circulating flu strains.

23 Oct 2013

Novozymes, Almac Ally To Offer Drug Targeting, Pharmacokinetics Service

...

23 Oct 2013

Biolinerx In-Licenses Type 1 Diabetes Treatment With Israel Institutions

...

23 Oct 2013

FDA grants Priority Review to Lilly's ramucirumab for treatment of advanced gastric cancer

Eli Lilly and Company today announced that the U.S. Food and Drug Administration has assigned Priority Review to the regulatory submission for ramucirumab (IMC-1121B) as a single-agent treatment for advanced gastric cancer following disease progression after initial chemotherapy.

23 Oct 2013

Scientists from University of Salzburg, Sandoz Pharmaceuticals and Thermo Fisher Scientific collaborate to advance protein-based pharmaceutical development

The Christian Doppler Laboratory for Biosimilar Characterization is now open at the Paris-Lodron University of Salzburg, and scientists there have commenced developing new methods for characterizing proteins to be used in biopharmaceuticals.

23 Oct 2013

FDA alerts on voluntary recall of sterile use products from Specialty Compounding

The U.S. Food and Drug Administration is alerting hospitals, health care providers, veterinarians, and patients of a voluntary recall of certain human and veterinary products produced and distributed for sterile use by Specialty Medicine Compounding Pharmacy of South Lyon, Mich.

23 Oct 2013

FDA seeks permanent injunction against dietary supplement manufacturer James G. Cole

The U.S. Food and Drug Administration, in a complaint filed by the U.S. Department of Justice, is seeking a permanent injunction against the dietary supplement manufacturer James G. Cole, Inc., its president, James G. Cole, and its general manager, Julie D. Graves, following the company's repeated distribution of unapproved drugs and adulterated dietary supplements in violation of the Federal Food, Drug, and Cosmetic Act.

23 Oct 2013

Pharmaceutical News

Diabetic patients may require higher doses of metformin to achieve same anti-cancer activity

Whitehead Institute scientists identify novel Parkinson's disease drug target

Study: Investigational drug shows promise against pancreatic cancer

Hands-free ultrasound device with clot-busting drug safe for ischemic stroke patients

Biolinerx Inks In-License Agreement With Israeli Institutions For Type 1 Diabetes Treatment

Nelsons introduces new hemorrhoid cream

Alexion Pharma's replacement therapy gets FDA Breakthrough Therapy designation for MoCD Type A

Leukemia drug reverses symptoms of colitis in lab tests

FDA to phase out all inhaler medical products containing CFCs by Dec. 31

Kaiser Permanente researchers named co-recipients of Drug Therapy Research Literature Award

Metformin could serve as radiosensitizer to treat patients with stage III non-small cell lung cancer

State-of-the-art HIV vaccine laboratory opens in Cape Town, South Africa

Testosterone treatment in hypogonadal men may reduce cardiovascular disease risk

New flu vaccine offers better protection against circulating flu viruses

Novozymes, Almac Ally To Offer Drug Targeting, Pharmacokinetics Service

Biolinerx In-Licenses Type 1 Diabetes Treatment With Israel Institutions

FDA grants Priority Review to Lilly's ramucirumab for treatment of advanced gastric cancer

Scientists from University of Salzburg, Sandoz Pharmaceuticals and Thermo Fisher Scientific collaborate to advance protein-based pharmaceutical development

FDA alerts on voluntary recall of sterile use products from Specialty Compounding

FDA seeks permanent injunction against dietary supplement manufacturer James G. Cole

Advancing Motor Neuron Disease Diagnosis with Non-Invasive Ultrasound and AI

How agentic AI is reshaping laboratory workflows

Fourier 80: bringing benchtop NMR systems to the laboratory

Latest News